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Background: As pharmaceutical firms experience increasing civil society pressure to act responsibly in a changing
globalized world, many are expanding and/or reforming their corporate social responsibility (CSR) strategies. We sought
to understand how multinational pharmaceutical companies currently engage in CSR activities in the developing world
aimed at global health impact, their motivations for doing so and how their CSR strategies are evolving.
Methods: We conducted a small-scale, exploratory study combining (i) an in-depth review of publicly available
data on pharmaceutical firms’ CSR with (ii) interviews of representatives from 6 firms, purposively selected,
from the highest earning pharmaceutical firms worldwide.
Results: Corporate social responsibility differed for each firm particularly with respect to how CSR is defined,
organizational structures for managing CSR, current CSR activities, and motivations for CSR. Across the firms studied,
the common CSR activities were: differential pharmaceutical pricing, strengthening developing country drug
distribution infrastructure, mHealth initiatives, and targeted research and development. Primary factors that
motivated CSR engagement were: reputational benefits, recruitment and employee satisfaction, better rankings
in sustainability indices, entrance into new markets, long-term economic returns, and improved population health.
In terms of CSR strategy, firms were at different points on a spectrum ranging from philanthropic donations to
integrated systemic shared value business models.
Conclusions: CSR is of increasing importance for multinational pharmaceutical firms yet understanding of the
array of CSR strategies employed and their effects is nascent. Our study points to the need to (i) develop clearer and
more standardized definitions of CSR in global health (2) strengthen indices to track CSR strategies and their public
health effects in developing countries and (iii) undertake more country level studies that investigate how CSR
engages with national health systems.
Keywords: Corporate social responsibility, Pharmaceutical firms, Global health, Emerging markets, Public-private
partnershipsBackground
Businesses and corporations in many sectors are initiat-
ing programs and strategies aimed at enhancing social
welfare, protecting the environment and defending hu-
man rights. There is evidence worldwide of the growing
importance and impact of corporate social responsibility
(CSR) [1]. For example, the recent United Nations (UN)
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article, unless otherwise stated.align objectives and interests of the business world and
global community to develop innovative policies aimed
at harnessing and leveraging the momentum of CSR [2].
Even more recently, the Government of India mandated
CSR by requiring for-profit entities to give 2% of their
net profits to charitable causes [3]. While there is ex-
tensive published literature on CSR and international
development the literature on CSR and global health
is limited [4,5]. A number of papers have explored
whether pharmaceutical companies are living up to
their human rights obligations [6-9], however, thisd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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sively, instead focusing narrowly on drug pricing or
product licensing. Other papers on CSR in multi-
national pharmaceutical companies have evaluated
specific CSR activities [10], focused on the creation of
economic opportunity [11], or presented more of an
industry perspective [12].
CSR is plagued by a multitude of definitions rooted
in different sources. At its broadest, CSR has been
defined as “the overall contribution of business to
sustainable development” [13], characterized as eco-
nomic development that does not undermine “the
ability of future generations to meet their own needs”
[14]. Others have envisaged it along a spectrum,
which ranges from giving because it is the “right
thing to do,” to risk management, all the way to cre-
ating shared value (CSV) which embeds social re-
sponsibility in the core of all corporate operations
attempting to simultaneously create benefits for the
company and society [15]. This study adopts the
European Commission’s definition of CSR as “the re-
sponsibility of enterprises for their impacts on soci-
ety.” This definition further recommends that firms
put in place processes “to integrate social, environ-
mental, ethical, human rights and consumer concerns
into their business operations and core strategy in
close collaboration with their stakeholders” [16]. The
notion of CSR rests upon the premise that most
modern firms likely create “bads” as well as goods,
and accordingly should conduct activities that deliver
social or environmental benefits to offset any adverse
consequences of their business.
Pharmaceutical companies are special cases because
their business decisions directly impact human health,
making CSR efforts particularly important. These
firms have been criticized for specific behaviors such
as setting prohibitively high prices and sluggishness in
responding to demands to provide access to life saving
drugs for poor populations [12]. In response, at least in
part, during the past two decades pharmaceutical compan-
ies have significantly increased CSR efforts, particu-
larly in low- and middle-income countries (LMICs)
that bear the large majority of the global disease bur-
den [17,18]. Recent epidemiological and demographic
shifts, notably the HIV/AIDS pandemic, have magni-
fied pressures to actively work to promote societal
well-being [10].
Pharmaceutical companies have been critiqued for
using CSR to repair compromised reputations or to re-
verse public beliefs about their commercial endeavors
being unethical [19]. This paper seeks to explore why
and how multinational pharmaceutical companies are
engaging in CSR to improve global health. Specifically,
we address the following questions:(i) What strategies and mechanisms do multinational
pharmaceutical companies use for corporate social
responsibility?
(ii) What motivates these companies to engage in CSR
that targets population health in LMICs?
(iii) How is understanding and conceptualization of
CSR in these firms evolving?
Our aim is to enhance understanding of CSR among
international public health experts and promote greater
discussion about how CSR can best be leveraged to im-
prove population health around the world.
Methods
We conducted a small scale, exploratory study of CSR in
six large multinational pharmaceutical firms. The study
consisted of two major components: first, interviews
with representatives from select firms; and second, a re-
view of publicly-available corporate social responsibility
documents which included firm- or industry-produced
documents and external reports on CSR in the firms. In
addition a non-exhaustive review of secondary literature
was undertaken to inform the analysis. Reviewing sec-
ondary literature helped to elucidate an understanding
of corporate social responsibility, its relationship with
health outcomes and the unique positioning of pharma-
ceutical firms in this field. This phase of work served
primarily to position our findings within the existing
landscape.
A review of several sourcesa determined that in the
past several years, the following 7 firms, listed in alpha-
betical order, were most consistently ranked among the
top 10 largest multinational pharmaceutical companies:
GlaxoSmithKline, Johnson and Johnson (Janssen), Merck
& Co., Novartis, Pfizer, Roche, and Sanofi. All of these
firms have active corporate social responsibility projects
related to health in LMICs, an important criteria for in-
clusion. All of these firms employed CSR in order to in-
tegrate social concerns into their corporate strategy in
LMIC contexts, as opposed to simply providing philan-
thropic donations unconnected to commercial strategy.
To set up interviews, firms were contacted using pub-
licly available information or through existing contacts
that we had with persons working in this field. Of all
firms contacted, only Sanofi refused to be interviewed
and was subsequently excluded from the analysis. All
initial contacts were made through email in Winter 2014
and 6 interviews with 7 individuals were carried out in
Spring 2014. The respondent provided for the interview
was at the firm’s discretion. One firm provided two re-
spondents, who were interviewed together. See the List
of Respondents’ Titles section below where positions are
presented in random order to preserve anonymity. The
interviews were semi-structured and responses were
Table 1 Organization: situating CSR within the corporation
A B C D E F
CSR Policies
Clearly articulated definition of CSR/CR X X X X
Clear Criteria for CR activities X X
Specific Policies (internal or external) dictating CR X X X
Positioning Within Firm
CR department X X X
CR steering committee/group X X X X X X
Separate philanthropy entity (i.e. foundation) X X
Sustainable business/shared value sector X X X
Systemic sustainable shared value business model X X
Partnership
With competing firms X X X X X
With other private for-profit entities X X X X X X
With local governments X X X X X X
With local and international NGOs X X X X X X
Reporting*
Independent X X X X X
Integrated X X X
*Refers to whether CR/CSR is incorporated into annual reports or a separate report
is generated (or both).
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The audio-recordings were not transcribed but were re-
ferred back to during analysis to supplement notes and
provide exact quotes. Interviewees were offered an in-
formed consent form, which guaranteed the masking of
firms’ identities in reference to their responses and abil-
ity to opt out of any questions they were not comfort-
able answering. All signed the consent form and agreed
to have the interview recorded. Respondents were all
asked the same general questions, with slightly different
follow-up inquiries where appropriate. Respondents were
asked specifically about CSR practices given their current
roles but responses were likely informed by prior experi-
ences as well. This study underwent ethical review and was
exempted by the Johns Hopkins Internal Review Board be-
ing classified as non-human subjects research.
To supplement the interviews, firms’ publicly-available
documentation on CSR was reviewed together with any
non-public reports provided by respondents. This in-
cluded but was not limited to: firm-provided CSR docu-
ments, annual reports, websites, published interviews
and press releases. The most recent versions were uti-
lized, usually from between 2010 to 2013; older sources
were referred to when necessary. Triangulation of the
interview responses, firm publications and secondary
sources produced the results presented below.
An earlier draft of this manuscript was shared with all
respondents to confirm information accuracy; appropri-
ate edits were incorporated based on feedback.
List of respondents’ titles
 Senior Manager, Corporate Responsibility
 Director, Public Engagement & Access Initiatives
 Vice President, Global Market Strategy
 Executive Director, Corporate Responsibility
 Communications Director, Sustainability and Access
to Healthcare
 Lead, New Markets Division
 Head of Corporate Responsibility Strategy &
Stakeholder Engagement
Findings
Firms included in the study sample are GlaxoSmithKline,
Janssen, Merck, Novartis, Pfizer and Roche. In presenting
findings, we have randomly replaced firm name with a let-
ter to preserve the anonymity of respondents and the firms
they represent.
CSR activities & organizational structure
CSR management is situated differently in each of the
included firms. Although all interviewees participated
directly in managing corporate social responsibility activ-
ities, job titles and departments varied. Table 1 representsways in which each firm incorporated CSR into its
organization.
Several of the firms have affiliated foundations that are
separate legal entities from the corporation and are pri-
marily responsible for philanthropic giving. Others in-
clude this philanthropy as part of their CSR. Firm E’s
respondent explained the breadth of their approach:
We view C[S]R as a spectrum ranging from
philanthropy to non-profit activities, to shared value
activities where we pursue initiatives that generate
societal value and economic value for the company.
—Respondent, Firm E
Table 1 shows that firms C and F have systemically in-
tegrated CSR efforts across commercial operational divi-
sions. This means that they do not have separate
responsibility arms and instead aim to incorporate these
values into all of their endeavors to form a business
model that generates value for both the enterprise and
communities it serves.
Pharmaceutical firms engage in a wide array of activ-
ities under the umbrella of CSR which is represented in
Table 2. These aggregated activities are limited to those
programs that were identified either in publicly available
documents produced by the firms themselves or in the
semi-structured interview. Across the world, all firms of-
fered differential pricing schemes for their products,
Table 2 CSR activities by pharmaceutical firm
A B C D E F
Product Involvement
Donation X X X X X
Differential pricing sales for resource poor countries X X X X X X
Special licensing agreements for resource-poor countries X X X X
Health Systems Strengthening
Training of health care workers X X X X
Improved local manufacturing X X X
Increased product distribution capacity X X X X X X
Infrastructure investment X X X
Supply-chain support X X X X
Private or informal provider engagement X X X X X
Promoting uptake of health insurance X X
Miscellanous
Loan & Microfinance programs X X X
mHealth initiatives X X X X X
Social marketing X
Health issue awareness campaigns X X X X
Advocacy and policy X
Targeted Research & Development* X X X X X X
International employee placement program X X X X
*Specifically to meet developing country health needs or products with no commercial potential.
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cording to a country’s economic viability. Product dona-
tions are central to pharmaceutical companies CSR; all
but one company indicated provision of drugs at no cost
to patients as part of their efforts. mHealth (mobile
health) initiatives were also popular among the firms.
An example of such an initiative is the development of
SMS-based appointment reminders for patients needing
provider-assisted treatments which helps with adherence
and supports firms’ pharmacovigilance. Five of the
firms worked directly with the private sector, which
sometimes included informal healthcare providers.
One example of this was Firm C’s program that pro-
vided loans and training to individuals looking to open
accredited pharmacies in the urban slums of some of
Africa’s largest cities. Almost all firms conducted spe-
cialized research to address diseases that exclusively
or disproportionately affect developing nations. This
was included as CSR since firms expect insignificant
financial returns on products being developed for
countries with negligible ability to pay.
According to the interviewees, CSR activities were al-
ways supported by partnerships involving local and
international partners, which were prominently featured
on the firms’ websites. Firms described partnerships with
telecommunications companies for their mHealth initia-
tives, banks for micro-loan schemes to increase patientpurchasing power, and community-based organizations
to encourage local buy-in and participation.
The decision-making process behind initiating specific
CSR activities varied across the included firms but was
often determined by the presence of existing in-country
networks, cooperative local government, alignment with
company expertise, and the ability to make health impact
in an area that was not over-saturated they could mean-
ingfully contribute to. While no firm identified specific ex-
clusion criteria concerning CSR activities, several cited
instances where they had foregone or withdrawn from an
opportunity. Firm A explains one of these circumstances:
About 2 or 3 years ago we looked at world hunger.
There was a lot of interesting marketing involved in
hunger initiatives and so we kind of put our toe in the
water, and I think we quickly realized that to make a
big difference or any difference in that space required
a huge investment and we would probably have to
reallocate […] most of our philanthropic resources into
that to make a difference. And as we looked at that,
we said yes, it’s a perfectly worthy thing to do but is it
the right fit for [us]? —Respondent, Firm A
In this quote, Firm A’s respondent alludes to “making
a difference”, which introduces the motivations that
drive firms to engage in CSR in the first place.
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Data presented in Table 3 show motivations for CSR en-
gagement that were disclosed in the interviews with firm
representatives. The categories were generated by the re-
searchers based on responses following the completion
of all interviews.
Population health impact was included by every firm
as a source of motivation, either in the interview or in
publicly available documents. The respondent from Firm
F stated that health was his firm’s “greatest asset […] and
the contract that we have is delivering what the patients
need,” positioning population health as central to the
firm’s purpose and alluding to its social obligation.
In direct response to why they work in developing
countries, Firm C’s respondent stated that investment
dollars could go further in LMICs, making CSR efforts
more cost-effective than they might be elsewhere; this
respondent went on to cite Africa as the “last frontier of
growth for many multinational companies.” Several re-
spondents indicated that by helping to create healthier
communities in developing countries, they were fueling
economic prosperity, increasing local purchasing power,
and thus opening doors to new markets for other pur-
suits by the same firm. Firm B’s respondent noted that
CSR was a “way to grow business in a global market-
place.” The same firm acknowledged that CSR initiatives
helped them gather market intelligence and learn about
health systems to inform decision making with regardsTable 3 Motivations identified by firm representatives
Reputational benefit
Perception of firm by consumers
Perception of firm by potential funders
Relationship and trust building with potential partners and stakeholders
Employee recruitment, satisfaction, engagement and innovation




Intelligence gathering on new markets
Anticipated long-term financial gain
Increased cost-effectiveness of interventions and programs (in developing co
Improved efficiencies
Opportunity for innovation
Special access to local government officials and decision making
Philanthropy & health impact
Obligation as a health care company
Improved population health impact
Increasing patient access to necessary medications/health services
*and/or Access to Medicine Index, Fortune World’s Most Admired Companies.to a new market. In this case, CSR work preceded
business presence and provided feedback that informed
business strategies for expansion into this market.
Others identified pre-commercialization CSR presence
as a way of building trust with local governments, non-
governmental organizations and consumers. This explains
why new market entry considerations are intrinsically
linked with external perceptions of a firm. Reputation was
the most frequently and readily cited reason for CSR by all
firms. All of the firms saw health, CSR, reputation and sus-
tainability as interrelated. Firm A exemplifies this:
From a commercial perspective, […] we feel very
strongly that being socially responsible and engaging in
activities that both advance our business objectives as
well as social objectives really will help the company
to be sustainable over the longer term. […] Engaged in
the business [of] health, it really does relate to trust
and you really live and die on how trusted you are by
patients and customers. […] Demonstrating a strong
commitment to C[S]R really helps to build trust with
key stakeholders—with patients and that will speak to
our long-term sustainability. –Respondent, Firm A
Cited by 4 of the 6 firms, appealing to potential em-
ployees was a common source of motivation driving pro-
grams that directly involve employees in CSR activities.
An employee exchange programs is one example of thisA B C D E F
X X X X
X
X X X
X X X X
X X X
X X X X X
X
X






X X X X X X
X X X X X X
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sponsored volunteerism where in-house employees are
placed with organizations in developing countries to
help them with their organizational governance and de-
velopment strategies. One respondent acknowledged
the importance of recruitment and its ties to reputation,
stating that his firm wants:
[…] to attract good employees [who] care about the
reputation of the company and whether the company
is ‘doing good’ –Respondent, Firm D
Evolving understanding of CSR
Firms are at different points in their integration and imple-
mentation of CSR. Many of them noted that their firm’s in-
ternal positioning of—and external position on—CSR was
“in transition.” One respondent acknowledged that his firm
was slow on the uptake and was looking to competitors
who were already “doing responsibility well” as exemplars.
Several respondents were determined that while creat-
ing economic value is essential to shareholders, CSR,
philanthropy and CSV initiatives can all be mechanisms
to benefit society simultaneous to commercial activities.
Firm B has placed philanthropy under their larger CSR
umbrella, noting that for healthcare companies the two
come from similar motivations. In contrast, Firms A and
D separated philanthropy and CSR indicating that
philanthropy should be wholly benevolent whereas CSR
seeks to create commercially sustainable models that
can be mutually beneficial to the firms and the recipient
societies. In Firm D, the respondent explained that CSR
currently straddles three major divisions of the company:
“corporate contributions, CSR & sustainability, and glo-
bal health industry,” crossing from philanthropic to
commercial and what lies between.
There was a clear lack of consensus on the definition
of CSR. A handful of firms did define CSR, either in the
interview or in official documents, each with different
wording or even meaning. A few firms expressed frustra-
tion about misconceptions of CSR among stakeholders
including implementing partners, governments, internal
constituents and consumers. Firm F cited a lack of un-
derstanding concerning CSR as hindering the private
sector’s ability to contribute to global health program-
matic development in LMICs. Critics, Firm F purports,
are contributing to this impediment:
Every push-back I hear is simply from people not
understanding what they’re talking about […];
inflammatory use of these terms is harming the
value of the ideas. –Respondent, Firm F
Several of the respondents identified the lack of key
performance indicators, best practices, transparency anddata as major challenges to achieving CSR objectives.
Some but not all firms did report using guidelines devel-
oped by the Global Reporting Initiative, an international
organization that promotes the use of CSR reporting as
a way for organizations to become more sustainable and
contribute to sustainable development.b Firm E perceived
the Dow Jones Sustainability Index,c Access to Medicine
Indexd and Fortune’s list of the World’s Most Admired
Companiese as measures of reputation, which are intangible
and hard to quantify. Several other firms also pointed to
these indices as important incentives for CSR engagement
by facilitating benchmarking of such activities. Firm F
stated the specific annual goal of being among the top 3
companies in the industry on the Dow Jones Sustainability
Index as a way of measuring and providing internal incen-
tives for different departments.
Discussion
To the best of our knowledge, this paper provides the
first portrait of why multinational pharmaceutical corpora-
tions are engaging in global health-related CSR activities.
All six firms interviewed had extensive CSR experience
encompassing diverse initiatives from mHealth to preferen-
tial drug pricing and employee exchange programs. An ex-
ternal assessment has shown that employee engagement in
CSR activities increases employee pride and loyalty,
improves other stakeholders’ perceptions of the firm, and
increases efficiency and impact of the host organization
[10]. Existing literature purports that responsible pharma-
ceutical firms will necessarily include diverse public-private
and private-private partnerships in their CSR agenda
[17,20], which was supported by this study’s sample. While
internal governance of CSR was diverse across the firms,
many of the motivations driving CSR were consistent.
Motivations offered by the firms can be generalized
into three interrelated categories: reputational benefit,
competitive advantage and philanthropic health impact. In-
creasing access to medicines and treatments as a means to
improving population health was the most commonly cited
motivation for CSR endeavors in LMICs. This push for
increasing access was closely linked to reputational benefit
for the respondents, which the firms in turn connected
to competitive advantage. CSR literature echoes many
of the motivations cited in this study, including factors
such as reputation building, opportunities for entering
new markets and moral arguments to protect and bet-
ter society [12,17,21,22].
Other research has found that pharmaceutical firms
are “beginning to realize that, in many cases, meeting
some needs of the underserved in LMICs may prove an
important source of future growth and profitability”
[20]. This is affirmed by firm respondents’ indications
that CSR strategies offer opportunities for exploring and
developing new markets in LMICs while simultaneously
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countries.
This study showed that pharmaceutical firms struggle
with how other actors perceive and define CSR and that
CSR is not even understood in the same way across the
pharmaceutical industry. In his analysis of pharmaceut-
ical firms’ CSR, Leisinger identifies a “wide pluralism of
values” in the industry, resulting in the multiplicity of
CSR definitions [12]. The UN offers vague suggestions
for different levels of CSR standards ranging from a
minimum where “businesses fulfill their legal obliga-
tions or, if laws or enforcement are lacking, that they
‘do no harm;’” to a maximum, which is “the active
alignment of internal business goals with externally set
societal goals (those that support sustainable develop-
ment)” [13].
While company respondents were aware and in some
cases focused on the various indices tracking CSR, the
lack of clarity around the definition of CSR can be prob-
lematic for these indices too. For example, the Access to
Medicine Index has seven different dimensions which
include philanthropy, quite separately from “general ac-
cess to medicines.” However, as this study has demon-
strated, the relationships between philanthropy and
broader access to medicines strategies vary substantively
across firms. The Dow Jones Sustainability Index is the
best established of the various CSR-related indices dis-
cussed but its focus is more on corporate sustainability
than public health concerns. The Access to Medicines
Index provides a much stronger focus on public health,
but as others have argued, has weaknesses including 30%
of indicators being “inadequately specified,” and some
key CSR dimensions (such as availability, access and af-
fordability of essential medicines) either being omitted
or inadequately weighted [23]. In order to improve
transparency and accountability, a common definition of
CSR needs to be adopted by pharmaceutical and health-
care companies, and the Access to Medicine index mea-
sures of CSR effort need to be further developed.
This study demonstrates that across the pharmaceut-
ical industry, multinational corporations are making
significant and diverse CSR efforts influencing health in
LMICs. There are substantial further questions for re-
search. First, while CSR initiatives are intended to de-
liver social benefits, it is possible that there may also
be unforeseen consequences; for example, training
certain health providers may squeeze others out of the
labor market [24]. This study did not address the
nature of CSR impacts on intended beneficiaries and
research in this area would be worthwhile. Second,
although pharmaceutical firms are building CSR initia-
tives on local partnerships, research is needed to in-
vestigate the extent to which such initiatives are truly
aligned with local policies and priorities. Finally, ourinterviews and document review did not reveal data con-
cerning the magnitude of resources currently invested in
CSR and further investigation of the resources CSR requires
is warranted.
Limitations
This was a small-scale exploratory study constrained by
the resources available to the researchers. Interviewees’
roles were not uniform across the firms and thus they
may be responding from the particular perspective of
their own position, rather than giving an overarching
view of the firm’s CSR practice. Nonetheless, we believe
that the combination of interviews and document review
provided a relatively comprehensive view of types of
CSR activities conducted, organizational structures for
managing CSR, and motivations for CSR across the sam-
ple of firms. It should be noted that only established
companies with relatively mature CSR strategies were in-
cluded in this study, and smaller companies with more
nascent CSR initiatives may offer different motivations
and perspectives.
Conclusions
This study highlights the increasingly important role
that corporate social responsibility is playing in large
pharmaceutical firms, and by extension in the health
sectors of low- and middle-income countries. While the
UN suggests that “CSR offers real opportunities for the
governments of middle and low-income countries to
change the terms on which they interact with business
[…] and to leverage additional resources through part-
nership” [13], the public health community is a long way
from understanding how best to go about this. Further-
more, several of the factors unveiled in this study seem
to limit the ability of the largest pharmaceutical com-
panies to maximize their resources and will to improve
the health of underserved populations.
Our study points to three key steps that should be
taken to help move forward the dialogue between the
CSR arms of large firms and people concerned about
public health in low- and middle-income countries. First,
there is a need for clearer definitions of the many terms
that are currently bandied around in this field, including
philanthropy, CSR and CSV. Pharmaceutical companies
suggest that misunderstanding of these terms leads to
doubts regarding their CSR efforts and motivations, but
it is clear that confusion also exists within the industry.
Second, existing indices to track the development, im-
plementation and effects of CSR strategies in the
pharmaceutical sector should be strengthened. Of the
available indicators the Access to Medicines Index is
best aligned with public health interests, but needs more
work in terms of garnering attention, promoting trans-
parency and ensuring that the indicators truly reflect
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the discussion, this exploratory study has suggested mul-
tiple further lines of enquiry, most of which would re-
quire country level studies to investigate in a more
detailed way how specific CSR initiatives have engaged
with country health systems and the impacts they have
made. It is clear that as CSR grows in significance the
global health community would be well-advised to invest
more in understanding this important practice.
Endnotes
aSources included firm-produced financial statements
and rankings from the following websites: FiercePharma,
Drug Watch, Forbes and PMLive.
bFor more information see: https://www.globalreporting.
org/information/sustainability-reporting/Pages/default.aspx.
cFor more information see: http://www.sustainability-
indices.com/.
dFor more information see: http://www.accesstomedici-
neindex.org/what-index.
eFor more information see: http://fortune.com/worlds-
most-admired-companies/.
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